Macter International Limited

MACTER

PK0113501016

Pharmaceuticals

End-of-day quote Pakistan S.E. Other stock markets 23:00:00 30/05/2024 BST			5-day change	1st Jan Change
86.96 ^PKR	-4.44%		-0.05%	-1.18%

03-12	Macter International Limited Announces Board Changes	CI
01-09	Macter International Limited Announces Appointment of Syed Naveed Rizvi as Chief Financial Officer, Effective from January 08, 2024	CI

Macter International Limited Announces Earnings Results for the Year Ended June 30, 2019

October 04, 2019 at 12:26 pm

Macter International Limited announced earnings results for the year ended June 30, 2019. For the year, the company reported net profit for the year of PKR 43,048,000 compared to PKR 246,283,000 a year ago. Turnover was PKR 4,194,932,000 compared to PKR 4,053,174,000 a year ago. Basic and diluted earnings per share was PKR 1.79 compared to PKR 6.29 a year ago.

Latest news about Macter International Limited

Macter International Limited Announces Board Changes	03-11	CI
Macter International Limited Announces Appointment of Syed Naveed Rizvi as Chief Financial Officer, Effective from January 08, 2024	01-09	CI
Macter International Limited Announces Resignation of Syed Anis Ahmed Shah as Director	12-13	CI
Macter International Limited Proposes Final Cash Dividend for the Financial Year Ending June 30, 2023	27/09/23	CI
Macter International Limited Announces Change of Director	08/05/23	CI
Macter International Limited Announces Cease of Tariq Wajid as Director	09/02/23	CI
Macter International Limited Announces Executive Changes	17/03/22	CI
Macter International Limited Announces Board Changes	20/01/22	CI
Macter International Limited Announces Cessation of Sohaib Umar as Director	25/10/21	CI
Macter International Limited Announces Unconsolidated Earnings Results for the Year Ended June 30, 2021	01/10/21	CI
Macter International Limited Recommends Cash Dividend for the Year Ended June 30, 2021	20/09/21	CI
Macter International Limited Announces Unaudited Earnings Results for the Second Quarter and Half Year Ended December 31, 2020	17/02/21	CI
Macter International Limited Declares Interim Cash Dividend	17/02/21	CI
Macter International Limited Announces Unconsolidated and Consolidated Earnings Results for the Year Ended June 30, 2020	05/10/20	CI
Macter International Limited Reports Unaudited Un-Consolidated and Consolidated Earnings Results for the Third Quarter and Nine Months Ended March 31, 2020	30/04/20	CI
Macter International Limited Reports Un-Consolidated and Consolidated Unaudited Financial Results for the Second Quarter and Six Months Ended December 31, 2019	26/02/20	CI
Macter International Limited Announces Unaudited Unconsolidated Earnings Results for the Quarter Ended September 30, 2019	29/10/19	CI
Macter International Limited Proposes Final Cash Dividend for the Year Ended June 30, 2019	04/10/19	CI
Macter International Limited Announces Earnings Results for the Year Ended June 30, 2019	04/10/19	CI
Macter International Limited Reports Unaudited Unconsolidated and Consolidated Earnings Results for the Quarter and Nine Months Ended March 31, 2019	30/04/19	CI
Macter International Limited Reports Un-Consolidated Unaudited Financial Results for the Second Quarter and Six Months Ended December 31, 2018	27/02/19	CI
Macter International Limited Reports Earnings Results for the Quarter Ended September 30, 2018	30/10/18	CI
Macter International Limited Reports Earnings Results for the Year Ended of June 30, 2018	03/10/18	CI
Macter International Limited Announces Executive Changes	03/10/18	CI
Macter International Limited Appoints Masarrat Misbah as its Director in Place of Muhammad Sajid	01/08/18	CI

Chart Macter International Limited

Duration

Period

More charts

Company Profile

Macter International Limited is a Pakistan-based pharmaceutical company. The principal activity of the Company is to manufacture and market pharmaceutical products. The Companyâs business areas are contract manufacturing and branded generic formulations. It is a contract manufacturer for multinational companies, which offers a range of dosage forms: oral solids and liquids, parenteral (ampules and vials), topicals, metered dose inhalers, ear and eye drops. Its contract manufacturing clients include a number of blue-chip multinationals. The Company produces specialty products at its high-tech plant. These include solid and liquid oral dosage forms (tablets, capsules, syrups, suspensions and dry powder), injections (sterile liquid vials, sterile liquid ampoules and sterile dry powders), ointments and creams, drops and inhalers. Its manufacturing operations include formulation, vial filling, lyophilization and packaging of biological drugs.

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
MACTER INTERNATIONAL LIMITED	-1.18%	14.98M
ELI LILLY AND COMPANY	+40.73%	734B
NOVO NORDISK A/S	+32.83%	591B
JOHNSON & JOHNSON	-6.30%	350B
MERCK & CO., INC.	+15.15%	315B
ABBVIE INC.	+4.05%	276B
ASTRAZENECA PLC	+15.00%	238B
NOVARTIS AG	+9.78%	206B
ROCHE HOLDING AG	-5.52%	204B
AMGEN INC.	+6.17%	161B

Other Pharmaceuticals